Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma

• DOI: 10.1111/exd.14864
• Publication Date: 2023-06-24T23:25:30Z
• Authors: Anita Y. Voigt; Andrew Walter; Timothy H. Young; John P. Graham; Bruna M. Batista ...; Alvaro de Mingo P...; Karol Prieto; Kenneth Y. Tsai; John P. Sundberg; Julia Oh
• Keywords: 0301 basic medicine; Skin Neoplasms; JGM; Ultraviolet Rays; Microbiota; 610; SS1; Anti-Bacterial Agents; Gastrointestinal Microbiome; 3. Good health; Mice; 03 medical and health sciences; RNA, Ribosomal, 16S; Carcinoma, Squamous Cell; Animals; Immunotherapy; Melanoma; JMG

The gut microbiome is increasingly recognized to alter cancer risk, progression and response treatments such as immunotherapy, especially in cutaneous melanoma. However, whether the influences immune checkpoint inhibitor (ICI) immunotherapy non-melanoma skin has not yet been defined. As squamous cell carcinomas (SCC) are closest proximity microbiome, we hypothesized that which regulates immunity, might affect SCC-associated anti-PD1 treatment response. We used ultraviolet radiation induce SCC SKH1 hairless mice. then treated mice with broad-band antibiotics deplete followed by colonisation candidate bacteria or persistent antibiotic treatment, all parallel ICI treatment. longitudinally monitored dynamics 16S rRNA gene sequencing tumour burden periodic measurements histologic assessment. Our study revealed antibiotics-induced abrogation of reduced burden, suggesting a functional role therapy